`

News & Analysis

Condos offering live/work space are hot

The age-old concept of living above your workplace is catching on again in Indianapolis, just as the developers of Douglass Pointe Lofts had hoped. The $2.65 million landmark at 25th and Delaware streets already will soon also be known for a diverse roster of local businesses.
Read More

NFL plan puts hit on Colts

A new National Football League policy could cost the Indianapolis Colts $56 million in league revenue sharing in the decade following the opening of Lucas Oil Stadium. The policy puts more pressure on the Colts to compete with revenue-generating giants such as the Washington Redskins and Dallas Cowboys.
Read More

Rising crime worries city businesses

Indianapolis fought long and hard to earn a reputation as a safe place to live and conduct business. But police statistics show that local security is eroding. Crime has risen to the highest levels seen during Mayor Bart Peterson's administration.
Read More

High-tech 21st Century funding in doubt

The first version of the $25.6 billion state budget, passed by the Democratic majority in the Indiana House of Representatives Feb. 22, didn't include any money for the Indiana 21st Century Research and Technology Fund, which provides financial assistance to promising high-tech startups.
Read More

Developer moving on after failed Crown Hill project

In the eyes of many at a rezoning hearing late last month, the developers from locally based Mann Properties were bad guys. They wanted to build homes and a retail center on 71 mostly wooded acres north of Crown Hill Cemetery. So when the Metropolitan Development Commission denied Mann's request, the crowd erupted in applause.
Read More

Dramatic facade change planned for office tower

The city's oldest skyscraper will get a sleek new look starting this summer, when workers are scheduled to begin installing a glass-covered curtain wall to replace a storm-scarred facade. Renovation of One Indiana Square should begin in June and continue for two years.
Read More

Lilly still breathing in inhaler pursuit

Pfizer Inc.'s new inhaled insulin product, Exubera, has stumbled out of the gate. That would appear to keep the door open for Eli Lilly and Co., as well as for other companies racing to develop inhaled insulin. But Pfizer's troubles might cause doctors and patients to sour on all inhaled insulin products.
Read More